ACE-Inhibition and Angiotensin II Receptor Blockers in Chronic Heart Failure: Pathophysiological Consideration of the Unresolved Battle

Cardiovascular Drugs and Therapy

Volumn 17, Issue 3, 2003, Pages 287-290

  Simko, F ^a   Simko, J ^a   Fabryova, M ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

ACE inhibitor; AT1 receptor blocker; AT2 receptor; ELITE II; Neurohormonal activation; OPTIMAAL; Tissue angiotensin II

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; BRADYKININ; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN; NITRIC OXIDE; PROSTACYCLIN; SPIRONOLACTONE; VALSARTAN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PREFERENCE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0242721462     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026215712983     Document Type: Article

References (28)

1. Pitt B, Segal R, Martinez FA, et al. on behalf of the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-752.
2. Pitt B, Poole-Wilson PA, Segal R, et al. on behalf of the ELITE II investigators. Effect of losartan compared with captopril in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
3. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effect of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Lancet 2002;360:752-760.
4. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptors blockers in heart failure: Meta-analysis of randomised controlled trials. J Am Coll Cardiol 2002;39:463-470.
5. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
6. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
7. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbid dinitrate in the treatment of congestive chronic heart failure. N Engl J Med 1991;325:303-310.
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
9. Pfeffer MA, Braunwald E, Moyé LA, et al. (on behalf of the SAVE investigators). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
10. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
11. Remme WJ, Swedberg K; European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:11-22.
12. Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology; American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. J Heart Lung Transplant 2002;21:189-203.
13. Weber KT, Sun Y, Katwa LC, Cleutjens JP. Connective tissue: A metabolic entity? J Mol Cell Cardiol 1995;27:107-120.
14. Urata H, Ganten G. Cardiac angiotensin II formation: The angiotensin-I converting enzyme and human chymase. Eur Heart J 1994;14(Suppl I):177-182.
15. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(Suppl):1L-20L.
16. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70-78.
17. Martineau P, Goulet J. New competition in the realm of rennin-angiotensin axis inhibition: The angiotensin II receptor antagonists in congestive heart failure. Ann Pharmacother 2001;35:71-84.
18. Pitt B. "Escape" of aldosterone production in patient with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drug Ther 1995;9:145-149.
19. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-1064.
20. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-57.
21. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: Distribution, signalling and function. Clin Sci 2001;100:481-492.
22. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Int Med 1992;117:234-242.
23. Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle (review). Physiol Res 2000;49:37-46.
24. Schneider MD, Lorell BH. AT2, judgment day. Which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation 2001;104:247-248.
25. Cohn JN, Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
26. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Charm-Programme Investigators. J Card Fail 1999;5:276-282.
27. Pfeffer M, McMurray J, Leizorovicz A, Maggioni AP, Reuleau J-L, Van de Werf F, for the VALIANT Investigators. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. Am Heart J 2000;140:727-734.
28. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999;341:10-19.